The British Journal of Cardiology

This site is intended for UK healthcare professionals

 
BJC_tv_logo_white
Sign in

Featured Videos #1

Amyloidosis signs and symptoms – red flags for cardiologists

Signs and symptoms of amyloidosis – red flags for cardiologists

This Masterclass was developed in collaboration with the National Amyloidosis Centre, London UK

Effective treatment of cardiac amyloidosis is dependent on early diagnosis; it is therefore important that clinicians have a high index of suspicion for the condition in their patients. Dr Josephine Mansell from the National Amyloidosis Centre outlines the “red flag” signs and symptoms that cardiologists, nurses or other healthcare professionals may observe in their patients, and which should prompt consideration of referral for a full diagnostic workup.

Digital transformations in cardiovascular medicine – where do we begin?

Dr Sarah Hudson and Charles Lowe discuss the latest advancements in digital innovation both supporting and challenging cardiology clinicians in the UK. Topol Fellow, Dr Hudson shares her wealth of knowledge and experience as a cardiologist with Charles Lowe, who’s worked in the digital healthcare space for over 25 years. In this fascinating conversation, we discover what is happening in cardiology clinics and what the future might hold for cardiologists. Look out for future videos covering these topics in more detail:

Urgent reversal of anticoagulants – lessons for practice

In recent years, there has been a switch to direct oral anticoagulants (DOACs) as first-line thrombosis prevention, with fewer people started on a vitamin K antagonist, such as warfarin. This has led to an increase in number of people taking anticoagulants and, therefore, an increased risk of intracranial and intracerebral haemorrhages and gastrointestinal bleeds. Listen to Richard Buka, Clinical Research Fellow Institute of Cardiovascular Sciences at the University of Birmingham, discuss the challenges clinical teams face in the reversal of these drugs. He explores the findings of recent trials of Andexanet alfa and considers how effective these drugs really are and what it means in practice.

The evolving role of a Cardio-oncology Clinical Nurse Specialist

The increasing survival rate of cancer patients along with the increase in the toxicity profile of treatments has resulted in a growing demand for specialist cardio-oncology care. Listen to Priya Reehal, Clinical Nurse Specialist at the Royal Brompton Hospital Centre of Excellence for Cardio-oncology, discuss her role, present the findings of a decade-long study into the number of patients referred for cancer therapy–related cardiac dysfunction, and explain why we need more cardio-oncology centres of excellence across the UK.

Cardiac inflammation: the fire within

Federica Marelli-Berg takes a look at some common and not-so-common causes of myocarditis, and the clinical manifestations cardiologists should consider.

ESC Congress 2024 highlights – A UK perspective: What’s new in the latest ESC guideline update?

Dr Paul Foley and Prof Terry McCormack share the key changes in the new ESC guidance on atrial fibrillation, hypertension and arterial disease.

AstraZeneca has provided a sponsorship towards this independent programme. AstraZeneca has had no editorial input into or control over the agenda, content development or choice of speakers, nor opportunity to influence except for the AstraZeneca sponsored symposia presentations. The remainder of the programme has remained under the full editorial control of the British Journal of Cardiology.

ESC Congress 2024 highlights – A UK perspective: New evidence on cardiovascular medical care

Dr Sarah Birkhoelzer and Dr Aaron Henry discuss hot topics and late-breaking abstracts from across the congress.

AstraZeneca has provided a sponsorship towards this independent programme. AstraZeneca has had no editorial input into or control over the agenda, content development or choice of speakers, nor opportunity to influence except for the AstraZeneca sponsored symposia presentations. The remainder of the programme has remained under the full editorial control of the British Journal of Cardiology.

 

Thanks for your feedback. Please note that by including your email address, you are giving permission for us to contact you by email to help resolve any issues.